WINNIPEG, MANITOBA--(MARKET WIRE)--Sep 5, 2007 -- Miraculins Inc. (CDNX:MOM.V - News) (the “Company”), a biotechnology company dedicated to the discovery and validation of cancer biomarkers for use in developing diagnostic tools and therapeutic products, has closed its previously announced private placement (the “Offering”) with aggregate gross proceeds to the Company of $428,000 from the sale of 1,222,858 units (the “Units”) at a price of $0.35 per Unit. Each Unit is comprised of one common share (a “Share”) and one-half of one Share purchase warrant (a “Warrant”). Each whole Warrant entitles the holder to purchase one Share at a price of $0.65 for a period of twelve months from the date of issuance of the Warrant. The net proceeds of the Offering shall be used for research and development and working capital purposes.
